Early monoclonal antibody combo for COVID-19 cuts hospital, death ratesYesterday in the New England Journal of Medicine results from a phase 3 trial showed that a combination of bamlanivimab plus etesevimab monoclonal antibodies led to a lower incidence of COVID-19–related hospitalization and deaths.The therapy also accelerated the decline in the SARS-CoV-2 viral load in patients who received the treatment, if administered within 3 days of diagnosis of mild to moderate COVID-19 in patients with at least one risk factor for developing serious disease.The trial including 1,095 patients who either received a single intravenous infusion of either a neutralizing monoclonal-antibody combination agent (2,800 milligrams [mg] of bamlanivimab and